Last reviewed · How we verify
NOVA63035 "Corticosteroid"
NOVA63035 is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors.
NOVA63035 is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors. Used for Inflammatory eye conditions (presumed, based on Santen's focus).
At a glance
| Generic name | NOVA63035 "Corticosteroid" |
|---|---|
| Sponsor | Santen SAS |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology or Dermatology |
| Phase | FDA-approved |
Mechanism of action
As a corticosteroid, NOVA63035 exerts anti-inflammatory effects through glucocorticoid receptor activation, reducing the production of pro-inflammatory cytokines and inhibiting immune cell activation. This mechanism makes it suitable for treating inflammatory and allergic conditions. The drug is marketed by Santen SAS, a company focused on ophthalmology and dermatology products, suggesting its primary use is likely in ocular or dermatological inflammatory conditions.
Approved indications
- Inflammatory ocular conditions (likely, based on Santen's focus)
Common side effects
- Local irritation or burning
- Increased intraocular pressure (if ophthalmic)
- Cataract formation (with prolonged use)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NOVA63035 "Corticosteroid" CI brief — competitive landscape report
- NOVA63035 "Corticosteroid" updates RSS · CI watch RSS
- Santen SAS portfolio CI